» Articles » PMID: 34436751

Repeatability of Image Features Extracted from FET PET in Application to Post-surgical Glioblastoma Assessment

Overview
Publisher Springer
Date 2021 Aug 26
PMID 34436751
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Positron emission tomography (PET) imaging using the amino acid tracer O-[2-(F)fluoroethyl]-L-tyrosine (FET) has gained increased popularity within the past decade in the management of glioblastoma (GBM). Radiomics features extracted from FET PET images may be sensitive to variations when imaging at multiple time points. It is therefore necessary to assess feature robustness to test-retest imaging. Eight patients with histologically confirmed GBM that had undergone post-surgical test-retest FET PET imaging were recruited. In total, 1578 radiomic features were extracted from biological tumour volumes (BTVs) delineated using a semi-automatic contouring method. Feature repeatability was assessed using the intraclass correlation coefficient (ICC). The effect of both bin width and filter choice on feature repeatability was also investigated. 59/106 (55.7%) features from the original image and 843/1472 (57.3%) features from filtered images had an ICC ≥ 0.85. Shape and first order features were most stable. Choice of bin width showed minimal impact on features defined as stable. The Laplacian of Gaussian (LoG, σ = 5 mm) and Wavelet filters (HLL and LHL) significantly improved feature repeatability (p ≪ 0.0001, p = 0.003, p = 0.002, respectively). Correlation of textural features with tumour volume was reported for transparency. FET PET radiomic features extracted from post-surgical images of GBM patients that are robust to test-retest imaging were identified. An investigation with a larger dataset is warranted to validate the findings in this study.

Citing Articles

Using high-repeatable radiomic features improves the cross-institutional generalization of prognostic model in esophageal squamous cell cancer receiving definitive chemoradiotherapy.

Gong J, Wang Q, Li J, Yang Z, Zhang J, Teng X Insights Imaging. 2024; 15(1):239.

PMID: 39373828 PMC: 11458848. DOI: 10.1186/s13244-024-01816-3.


Enhancing Interoperability and Harmonisation of Nuclear Medicine Image Data and Associated Clinical Data.

Fuchs T, Kaiser L, Muller D, Papp L, Fischer R, Tran-Gia J Nuklearmedizin. 2023; 62(6):389-398.

PMID: 37907246 PMC: 10689089. DOI: 10.1055/a-2187-5701.


Radiomics in Determining Tumor-to-Normal Brain SUV Ratio Based on C-Methionine PET/CT in Glioblastoma.

Danilov G, Kalayeva D, Vikhrova N, Konakova T, Zagorodnova A, Popova A Sovrem Tekhnologii Med. 2023; 15(1):5-11.

PMID: 37388754 PMC: 10306961. DOI: 10.17691/stm2023.15.1.01.


Feasibility of radiomic feature harmonization for pooling of [F]FET or [F]GE-180 PET images of gliomas.

Zounek A, Albert N, Holzgreve A, Unterrainer M, Brosch-Lenz J, Lindner S Z Med Phys. 2023; 33(1):91-102.

PMID: 36710156 PMC: 10068577. DOI: 10.1016/j.zemedi.2022.12.005.

References
1.
Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

2.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

3.
Shukla G, Alexander G, Bakas S, Nikam R, Talekar K, Palmer J . Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017; 6(4):40. DOI: 10.21037/cco.2017.06.28. View

4.
Galldiks N, Langen K . Amino acid PET in neuro-oncology: applications in the clinic. Expert Rev Anticancer Ther. 2017; 17(5):395-397. DOI: 10.1080/14737140.2017.1302799. View

5.
Langen K, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D . O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006; 33(3):287-94. DOI: 10.1016/j.nucmedbio.2006.01.002. View